IL17A and psoriasis vulgaris: Biologics targeting IL-17A alone or in combination with IL-17F or the IL-17 receptor A (IL-17RA) are efficacious in the treatment of plaque psoriasis, highlighting the central role of the IL-17A pathway in psoriasis pathogenesis (12).